Drug intelligence / Profile preview

Compound Danshen Dripping Pill

Development stage: Unknown
Lead developer: Tasly Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Compound Danshen Dripping Pill (CDDP), also known as T89, is a standardized traditional Chinese medicine (TCM) formulation developed by Tasly Holding Group. It is composed of extracts from *Salvia miltiorrhiza* (Danshen) and *Panax notoginseng*, along with synthetic borneol. Originally approved in China in 1994 for the treatment of coronary heart disease and angina pectoris, it is currently being investigated in a Phase 4 clinical trial (MAIDS study) by Qilu Hospital of Shandong University for the treatment of diabetic microvascular angina. The drug's therapeutic effects are attributed to its ability to improve vascular endothelial function, exert anti-inflammatory and antioxidative effects, and promote vasodilation, thereby enhancing coronary flow reserve (CFR) and microcirculation in patients with coronary microvascular dysfunction.

Brand names: Compound Danshen Dripping Pill
Other names: Fufang Danshen DiwanDanshen Dripping Pill

Targets

MET (Mesenchymal-epithelial transition factor receptor)PPARG (Peroxisome proliferator-activated receptor gamma)SYK (Spleen Tyrosine Kinase)PIM1 (Proviral integration site for moloney murine leukemia virus kinase 1)JNK (Mitogen-activated protein kinase kinase kinase family)

Beyond the preview

Go deeper on Compound Danshen Dripping Pill.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Compound Danshen Dripping Pill.

Explore the full profile